VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent

    - First Product Developed from the VisEn-Merck & Co., Inc. Biomarker

Imaging Program -



    - Expands VisEn's Leading Fluorescence Molecular Imaging Agent

Portfolio and Broadens Applications in Key Areas of Disease Research and

Drug Development -



    BEDFORD, Mass., Aug. 19 /EMWNews/ -- VisEn Medical, Inc., a leader

in fluorescence in vivo imaging from research through medicine, announced

today the commercial launch of its IntegriSenseTM fluorescence in vivo

imaging agent product line. The agent is the first product developed out of

the Merck-VisEn Biomarker Imaging research collaboration announced in 2007,

and will enable researchers to image and assess the role of integrin alpha

v beta 3 in disease progression and therapeutic response in vivo.



    IntegriSense is an optimized in vivo fluorescence imaging agent

targeting integrin alpha v beta 3, a key biomarker closely associated with

disease-related vascularity and angiogenesis. The agent was developed to

enable in vivo imaging of integrin alpha v beta 3 expression in order to

measure and monitor aspects of disease progression and therapeutic response

in disease states including oncology, cardiovascular disease, and bone

disease.



    "The integrin alpha v beta 3 protein plays an important key role in

many disease pathways, which is one of the key reasons we selected this as

a first imaging target with our collaborators at Merck," said Kirtland

Poss, President and CEO of VisEn Medical. "IntegriSense should enable

researchers to drive valuable new insights into disease progression and

therapeutic mechanisms of action in vivo. We are pleased to be providing

our customers the continually expanding ability to generate such rich

information on their disease biologies and pathways of interest."



    VisEn's in vivo fluorescence imaging technologies, including its

Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic

Imaging Systems (FMT), provide the industry's most robust fluorescence

molecular imaging performance in identifying, characterizing and

quantifying ranges of disease biomarkers in vivo. All of the VisEn imaging

agents are designed for use with VisEn's Quantitative Tomographic FMT

imaging systems to enable quantitative data on biological targets in vivo.

They are also compatible with a range of additional fluorescence imaging

systems, including planar systems and intravital microscopes.



    Additional product information can be obtained by calling Customer

Support at VisEn Medical: 781-932-6875, ext. 315, via email at:

[email protected]; or at http://www.visenmedical.com.

    About VisEn Medical



    VisEn Medical develops and commercializes the industry's highest

performing fluorescence in vivo imaging technology platforms, from research

through medicine. Founded in 2000 based on fluorescence in vivo imaging

technologies developed by industry-leading researchers and clinicians at

the Massachusetts General Hospital and Harvard Medical School, VisEn's FMT

Fluorescence Tomography imaging systems and suite of molecular imaging

agents are used to quantify biological mechanisms of disease and

therapeutic response in vivo. These systems are widely used by leading

research institutions and pharmaceutical companies in disease areas

including oncology, inflammation, cardiovascular, skeletal and pulmonary

diseases. The Company also works with pharmaceutical and clinical partners

to design and develop ranges of tailored molecular imaging agents and

applications that are targeted to their specific pre-clinical and clinical

research areas. For further information please visit http://www.visenmedical.com.